

**LA JOLLA PHARMACEUTICAL COMPANY**

**Consolidated Statements of Operations**

(in thousands, except per share amounts)

	Three Months Ended December 31, (unaudited)		Year Ended December 31,	
	2015	2014	2015	2014
<b>Revenue</b>				
Contract revenue - related party	\$ 410	\$ —	\$ 1,057	\$ —
<b>Total revenue</b>	<b>410</b>	<b>—</b>	<b>1,057</b>	<b>—</b>
<b>Expenses</b>				
Research and development	9,455	3,726	29,092	9,944
General and administrative	2,813	3,137	13,934	11,396
<b>Total expenses</b>	<b>12,268</b>	<b>6,863</b>	<b>43,026</b>	<b>21,340</b>
Loss from operations	(11,858)	(6,863)	(41,969)	(21,340)
Other income, net	25	14	57	27
<b>Net loss</b>	<b>\$ (11,833)</b>	<b>\$ (6,849)</b>	<b>\$ (41,912)</b>	<b>\$ (21,313)</b>
<b>Basic and diluted net loss per share</b>	<b>\$ (0.69)</b>	<b>\$ (0.45)</b>	<b>\$ (2.68)</b>	<b>\$ (2.00)</b>
Shares used in computing basic and diluted net loss per share	17,200	15,226	15,651	10,667

**LA JOLLA PHARMACEUTICAL COMPANY**

**Consolidated Balance Sheets**

(in thousands, except share and par value amounts)

	<u>December 31, 2015</u>	<u>December 31, 2014</u>
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 126,467	\$ 48,555
Restricted cash	237	37
Prepaid clinical expenses	223	1,528
Prepaid expenses and other current assets	618	137
Total current assets	<u>127,545</u>	<u>50,257</u>
Property and equipment, net	1,732	279
Other assets	70	—
<b>Total assets</b>	<b><u>\$ 129,347</u></b>	<b><u>\$ 50,536</u></b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 2,506	\$ 730
Accrued expenses	1,224	926
Accrued payroll and related expenses	1,090	424
Total current liabilities	<u>4,820</u>	<u>2,080</u>
Shareholders' equity:		
Common Stock, \$0.0001 par value; 100,000,000 shares authorized, 18,244,009 and 15,225,980 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively	2	2
Series C-1 <sup>2</sup> Convertible Preferred Stock, \$0.0001 par value; 11,000 shares authorized, 3,906 and 3,917 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively, and a liquidation preference of \$3,906 and \$3,917 at December 31, 2015 and 2014, respectively	3,906	3,917
Series F Convertible Preferred Stock, \$0.0001 par value; 10,000 shares authorized, 2,737 and 2,798 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively, and liquidation preference of \$2,737 and \$2,798 at December 31, 2015 and 2014, respectively	2,737	2,798
Additional paid-in capital	646,408	528,353
Accumulated deficit	(528,526)	(486,614)
Total shareholders' equity	<u>124,527</u>	<u>48,456</u>
<b>Total liabilities and shareholders' equity</b>	<b><u>\$ 129,347</u></b>	<b><u>\$ 50,536</u></b>